Pharmacological management of Huntington's disease: An evidence-based review

Current Pharmaceutical Design

Volumn 12, Issue 21, 2006, Pages 2701-2720

  Bonelli, Raphael M ^a   Wenning, Gregor K ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Chorea; Huntington's disease; Neuroleptics; Neuroprotection; Therapy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BUSPIRONE; CLOZAPINE; CREATINE; FLUPHENAZINE; HALOPERIDOL; KETAMINE; LEVODOPA; LITHIUM; MILACEMIDE; MINOCYCLINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; REMACEMIDE; RILUZOLE; RISPERIDONE; SERTRALINE; TETRABENAZINE; UBIDECARENONE; UNINDEXED DRUG; UNSATURATED FATTY ACID; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; BEHAVIOR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; EVIDENCE BASED MEDICINE; EYE MOVEMENT DISORDER; FATIGUE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LEUKOPENIA; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; PUBLICATION; REVIEW; SEIZURE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING DIFFICULTY;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; HUNTINGTON DISEASE; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33745759912     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698693     Document Type: Review

References (292)

1. Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004; 19(2): 51-62.
2. Movement Disorder Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17(Suppl 4): S1-166.
3. Kieburtz K, Shoulson I. Therapeutic trials in Huntington's disease. In: Bates G, Harper P, Jones L, editors. Huntington's disease. 3 ed. Oxford: Oxford University Press; 2002; p. 501-11.
4. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984; 47(8): 844-7.
5. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9(5): 329-38.
6. Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982; 65(1): 45-50.
7. Gimenez-Roldan S, Mateo D. Enfermedad de Huntington: tetrabenacina comparada con haloperidol en la reduccion de los movimientos involuntarios. Neurologia 1989; 4(8): 282-7.
8. Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985; 35(10): 1450-4.
9. Leonard DP, Kidson MA, Shannon PJ, Brown J. Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea. Lancet 1974; 2(7890): 1208-9.
10. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988; 38(1): 84-8.
11. Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 47(8): 848-52.
12. Caraceni T, Giovannini P, Girotti F, Avanzini G. Pharmacology of Huntington's chorea. Personal experience. Eur Neurol 1977; 16(1-6): 42-50.
13. Leonard DP, Kidson MA, Brown JG, Shannon PJ, Taryan S. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry 1975; 9(2): 115-8.
14. Kivalo E, Weckman N. Use of haloperidol in the treatment of extrapyramidal compulsive movement. Nervenarzt 1970; 41(11): 567-9.
15. Saran BM, Klein MS, Benay EM. Clinical evaluation of amantadine and haloperidol in Huntington's chorea. J Clin Psychiatry 1980; 41(6): 221.
16. Manyam NV, Bravo-Fernandez E. Lithium carbonate in Huntington's chorea. Lancet 1973; 1(7810): 1010.
17. Nayrac P, Arnott G, Milbled G. Huntington's Chorea, Humor Disorders with Manic Manifestations, Beneficial Effects of Haloperidol (Fluorophenylpiperidinobutyrophenone). Absence of the Therapeutic Akineto-Hypertonic Syndrome. Encephale 1964; 53: Suppl: 221-7.
18. Nayrac P, Arnott G, Milbled G. Huntington's Chorea, Temperament Disorders of Maniac Expression. Beneficial Effects of Haloperidol (Fluoro-Phenyl-Piperidine Butyrophenone). Absence of the Therapeutic Akineto-Hypertonic Syndrome. Lille Med 1964; 12: 765-8.
19. Borghesi R. On a case of Huntington's chores treated with Haloperidol. Rass Studi Psichiatr 1962; 51: 813-8.
20. Terrence CF. Fluphenazine decanoate in the treatment of chores: a double-blind study. Curr Ther Res Clin Exp 1976; 20(2): 177-83.
21. Whittier JR, Korenyi C. Effect of oral fluphenazine on Huntington's chorea. Int J Neuropsychiatry 1968; 4(1): 1-3.
22. Korenyi C, Whittier JR. Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin). Psychiatr Q 1967; 41(2): 203-10.
23. Chouza C, Romero S, Lorenzo J, Camano JL, Fontana AP, Alterwain P, et al. Traitement des dyskinesies par le tiapride Clinical trial of tiapride in patients with dyskinesia. Sem Hop 1982; 58(12): 725-33.
24. Quinn N, Marsden CD. Tiapride in 12 Huntington's disease patients. J Neurol Neurosurg Psychiatry 1985; 48(3): 292.
25. Arena R, Iudice A, Virgili P, Moretti P, Menchetti G. Huntington's disease: clinical effects of a short-term treatment with pimozide. Ady Biochem Psychopharmacol 1980; 24: 573-5.
26. Siegmund R, Schmeisser G, Heidrich R. Therapeutic experiences in the treatment of hyperkineses with the neuroleptic pimozide (Antalon, Orap) in the frame of Huntington chorea. Psychiatr Neurol Med Psychol (Leipz) 1982; 34(5): 307-8.
27. Bobon DP, Devroye A, Goffioul L, Pinchard A. Pimozide: 16 months of follow-up. Acta Neurol Psychiatr Belg 1968; 68(12): 887-94.
28. Lai S, De la Vega C, Garelis E, Sourkes TL. Apomorphine, pimozide, L-Dopa and the probenecid test in Huntington's chores. Psychiatr Neurol Neurochir 1973; 76(2): 113-7.
29. Knowling MR, Wrench W. Treatment of Huntington's chorea with sulpiride. S Afr Mod J 1991; 79(3): 169.
30. Neundorfer B, Rad Mv. Treatment of choreatic disorders with thiopropazate (Dartal). Nervenarzt 1971; 42(6): 330-2.
31. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974; 1(7848): 104-7.
32. Bruyn GW. Thiopropazate dihydrochloride (Dartal) in the treatment of Huntington's chorea. Psychiatr Neurol Neurochir 1962; 65: 430-8
33. Vaisberg M, Saunders JC. Treatment of Dyskinesias Including Huntington's Chorea with Thiopropazate and R-1625. Dis Nerv Syst 1963; 24: 499-500.
34. Lyon RL. Drug treatment of Huntington's chorea. A trial with thiopropazate. Br Med J 1962; 5288: 1308-10.
35. Tarighati S, a'Brook MF. Trifluperidol in Huntington's chorea. Lancet 1968; 2(7565); 458-9.
36. Joncev V, Mitkov V. Treatment of choreic hyperkinesias with thioproperazine (Majeptil). Folia Med 1971; 13(6): 339-44.
37. Podiwinsky F, Roth. On the phenothiazine treatment of Huntington's chores. Wien Med Wochenschr 1963; 113: 434-6.
38. Cohen NH. The treatment of Huntington's chores with trifluoperazine (Stelazine). J Nerv Ment Dis 1962; 134: 62-71.
39. Falm S. Treatment of choreic movements with perphenazine. Dis Nerv Syst 1972; 33(10): 653-8.
40. Merskey H, Rice T, Troupe A. An investigation of some therapeutic and physiological effects of perphenazine in Huntington's chorea. Psychopharmacologia 1961; 2: 436-45.
41. Riser M, Gayral L, Stern H, Turnin J, Millet L. Treatment of Huntington's chores with chlorpromazine (largactil) and thioridazine (melleril). Rev Otoneuroophtalmol 1959; 31: 498-501.
42. Mattsson B, Boman K. Buronil in Huntington's chorea. Lancet 1974; 2(7892): 1323.
43. Dursun SM, Burke JG, Andrews H, Mlynik-Szmid A, Reveley MA. The effects of antipsychotic medication on saccadic eye movement abnormalities in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(6): 889-96.
44. Moskowitz CB, Marder K. Palliative care for people with late-stage Huntington's disease. Neurol Clin 2001; 19(4): 849-65.
45. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986; 36(2): 244-9.
46. Schott K, Ried S, Stevens I, Dichgans J. Neuroleptically induced dystonia in Huntington's disease: a case report. Eur Neurol 1989; 29(1): 39-40.
47. Louis ED, Lee P, Quinn L, Marder K. Dystonia in Huntington's disease: prevalence and clinical characteristics, Mov Disord 1999; 14(1): 95-101.
48. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine Treatment for Huntington's Disease-Associated Chorea. Clin Neuropharmacol 2002; 25(6): 300-2.
49. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study, Ann Neurol 1982; 11(1): 41-7.
50. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981; 31(8): 1051-4.
51. Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972; 35(2): 186-88.
52. Gilligan BS, Wodak J, Veale JL, Munro OR. Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med J Aust 1972; 2(19): 1054-6.
53. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48(2): 358-62.
54. Jankovic; J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38(3): 391-4.
55. Toglia JU, McGlamery M, Sambandhant RR. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. J Clin Psychiatry 1978; 39(1): 81-7.
56. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976; 1(16): 583-4.
57. Astin KJ, Gumpert EW. Tetrabenazine in chorea. Lancet 1974; 1(7856):512.
58. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott Med J 1972; 17(11): 367-70.
59. Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand 1968; 44(3): 391-3.
60. Dalby MA. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J 1969; 2(654): 422-3.
61. Fog R, Pakkenberg H. Combined nitoman-pimozide treatment of Huntington's chores and other hyperkinetic syndromes. Acta Neurol Scand 1970; 46(2): 249-51.
62. Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust 1979; 1(13): 628-30.
63. McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. N Z Med J 1976; 83(558): 114-6.
64. Soutar CA. Tetrabenazine for Huntington's chorea. Br Med J 1970; 4(726): 55.
65. Moller-Christensen B, Videbech T. Treatment of Huntington's chorea with tetrabenazine (Nitoman). Ugeskr Laeger 1963; 125: 207-9.
66. Paleacu D, Giladi N, Moore O, Stem A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004; 27(5): 230-3.
67. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981; 31(8): 1022-5.
68. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992; 15(1): 63-8.
69. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996; 11(1): 95.
70. Snaith RP, Warren HD. Treatment of Huntington's chorea with tetrabenazine. Lancet 1974; 1(7854): 413-4.
71. Calabrese VP. Reserpine action in Huntingtons chorea. N Engl J Med 1973; 289(2): 104.
72. Kempinsky WH, Boniface WR, Morgan PP, Busch AK. Reserpine in Huntington's chorea. Neurology 1960; 10: 38-42.
73. Zmorski T. Reserpine (serpasin) in therapy of Huntington's chorea.. Psychiatr Neurol (Basel) 1959; 137(1): 40-8.
74. Chhuttani PN, Singh S. Reserpine in Huntington's chorea. J Indiana State Med Assoc 1959; 32(10): 402-3.
75. Vorisek V. Reserpine treatment of Huntington's chorea & other extrapyramidal syndromes. Cesk Neurol 1958; 21(2): 99-105.
76. Lazarte JA, Petersen MC, Baars CW, Pearson JS. Huntington's chorea: results of treatment with reserpine. Mayo Clin Proc 1955; 30(16): 358-65.
77. Chandler JH. Reserpine in the treatment of Huntington's chorea. Med Bull (Ann Arbor) 1955; 21(4): 95-100.
78. Markham CH, Clark WG, Winters WD. Effect of Alpha-Methyl Dopa and Reserpine in Huntington's Chores, Parkinson's Disease and Other Movement Disorders. Life Sci 1963; 18: 697-705.
79. Tyler A, Scourfield J, Morris M. Management and therapy of Huntington's disease. In: Harper P, editor. Huntington's disease. 2 ed. London: Saunders Company 1996; p. 161-200.
80. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14(1): 69-72.
81. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105(6):441-4.
82. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's Disease: An Open Label Study. Clin Neuropharmacol 2002; 25(5): 263-5.
83. Jimenez Jimenez FJ, De Toledo M, Puertas I, Baron M, Zurdo M, Barcenilla B. Olanzapine improves chorea in patients with Huntington's disease. Rev Neurol 2002; 35(6): 524-5.
84. Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002; 17(2): 91-3.
85. Bonelli RM, Niederwieser G, Diez J, Koltringer P. Riluzole and olanzapine in Huntington's disease. Eur J Neurol 2002; 9(2): 183-4.
86. Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington's disease. J Clin Psychopharmacol 2001; 21(2): 245-6.
87. Grove VE, Jr., Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000; 343(13): 973-4.
88. Etchebehere EC, Lima MC, Passos W, Maciel Junior JA, Santos AO, Ramos CD, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Arq Neuropsiquiatr 1999; 57(3B): 863-6.
89. Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report J Neurol Neurosurg Psychiatry 1999; 67(1): 123-4.
90. Laks J, Rocha M, Capitao C, Domingues RC, Ladeia G, Lima M, et al. Functional and motor response to low dose olanzapine in Huntington's disease: case report. Arq Neuropsiquiatr 2004; 62(4): 1092-4.
91. Bonelli RM. Olanzapine-associated seizure. Ann Pharmacother 2003; 37(1): 149-50.
92. Benazzi F. Rapid onset of tardive dyskinesia in huntington disease with olanzapine. J Clin Psychopharmacol 2002; 22(4): 438-9.
93. Erdemoglu AK, Boratav C. Risperidone in chores and psychosis of Huntington's disease. Eur J Neurol 2002; 9(2): 182-3.
94. Madhusoodanan S, Brenner R, Moise D, Sindagi J, Brafman I. Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. Ann Clin Psychiatry 1998; 10(3): 117-20.
95. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998; 6(4): 347-9.
96. Dallocchio C, Buffs. C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chores patients. J Clin Psychopharmacol 1999; 19(1): 101-3.
97. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997; 17(2): 134-5.
98. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002; 249(8): 1114-5.
99. Bonelli RM, Niederwieser G, Lahousen T, Hofmann P. Zotepine in Huntington's disease. Hum Psychopharmacol 2003; 18(3): 227-9.
100. Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol 2003; 17(4): 459-60.
101. Schmidt EZ, Hofmann P, Kapfhammer HP, Bonelli RM. Drug holiday in Huntington's disease. Ann Pharmacother 2005; 39(4): 773.
102. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63(1): 35-9.
103. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136(3): 317-20.
104. Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease. Neurology 1995; 45(5): 1023-4.
105. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chores. Neurology 1994; 44(5): 821-3.
106. Vallette N, Gosselin O, Kahn JP. Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case. Encephale 2001; 27(2): 169-71.
107. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 1991; 41(1): 156.
108. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990; 13(7): 286-9.
109. Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJ, Hariharan M, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997; 49(1): 153-61.
110. Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992; 15(2): 148-51.
111. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, et al. Huntington's disease: a randomized, controlled trial using the NMDA- antagonist amantadine. Neurology 2002; 59(5): 694-9.
112. Lucetti C, Del Dotto P, Gambaccini G, Dell'Agnello G, Bernardini S, Rossi G, et al. IV amantadine improves chores, in Huntington's disease An acute randomized, controlled study. Neurology 2003; 60(12): 1995-7.
113. Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G, et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2002; 23(Suppl 2): S83-4.
114. O'Suilleabhain P, Dewey RB, Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003; 60(7): 996-8.
115. Heckmann JM, Legg P, Sklar D, Fine J, Bryer A, Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004; 63(3): 597-8.
116. Gray MW, Herzberg L, Lerman JA, Turnbull MJ, Victoratos G. Amantadine in chorea. Lancet 1975; 2(7925): 132-3.
117. Scotti G, Spinnler H. Amantadine and Huntington's chorea. N Engl J Med 1971; 285(23): 1325-6.
118. Stewart JT. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J 1987; 80(10): 1324-5.
119. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996; 11(3): 273-7.
120. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57(3):397-404.
121. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61(11): 1551-6.
122. Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001; 248(10): 866-9.
123. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999; 14(2): 326-30.
124. Bodner T, Jenner C, Benke T, Ober A, Seppi K, Fleischhacker WW. Intoxication with riluzole in Huntington's disease. Neurology 2001; 57(6):1141-3.
125. Bonelli RM, Niederwieser G. Apraxia of eyelid closure in Huntington's disease. J Neural Transm 2002; 109(2): 197-201.
126. Perry TL, Hansen S, Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med 1973; 288(7): 337-42.
127. Glaeser BS, Vogel WH, Oleweiler DB, Hare TA. GABA levels in cerebrospinal fluid of patients with Huntington's chorea: a preliminary report. Biochem Med 1975; 12(4): 380-5.
128. Manyam BV, Tremblay RD. Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. Brain Res 1984; 307(1-2): 217-23.
129. Manyam NV, Hare TA, Katz L. Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. Life Sci 1980, 26(16): 1303-8.
130. Manyam BV, Katz L, Hare TA, Kaniefski K, Tremblay RD. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Ann Neurol 1981; 10(1): 35-7.
131. Manyam BV, Ferraro TN, Hare TA. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain Res 1987; 408(1-2): 125-30.
132. Manyam BV, Giacobini E, Colliver JA. Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntingtons disease. J Neurol 1990; 237(5): 281-4.
133. Perry TL, Wright JM, Hansen S, Thomas SM, Allan BM, Baird PA, et al. A double-blind clinical trial of isoniazid in Huntington disease. Neurology 1982; 32(4): 354-8.
134. McLean DR. Failure of isoniazid therapy in Huntington disease. Neurology 1982; 32(10): 1189-91.
135. Perry TL, MacLeod PM, Hansen S. Treatment of Huntington's chorea with isoniazid. N Engl J Med 1977; 297(15): 840.
136. Perry TL, Wright JM, Hansen S, MacLeod PM. Isoniazid therapy of Huntington disease. Neurology 1979, 29(3): 370-5.
137. Stober T, Schimrigk K, Holzer G, Ziegler B. Quantitative evaluation of functional capacity during isoniazid therapy in Huntington's disease. J Neurol 1983; 229(4): 237-45.
138. Seigliano G, Giovannini P, Girotti F, Grassi MP, Caraceni T, Schechter PJ. Gamma-vinyl GABA treatment of Huntington's disease. Neurology 1984; 34(1): 94-6.
139. Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA. THIP treatment of Huntington's disease. Neurology 1983, 33(5): 637-9.
140. Goetz CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, et al. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 1990; 5(3): 263-5.
141. Perry TL, Wright JM, Hansen S, Allan BM, Baird PA, MacLeod PM. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 1980; 30(7 Pt 1): 772-5.
142. Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978; 4(3): 279-84.
143. Paulson GW. Lioresal in Huntingtons disease. Dis Nerv Syst 1976; 37(8): 465-7.
144. Anden NE, Dalen P, Johansson B. Baclofen and lithium in Huntington's chorea. Lancet 1973; 2(7820): 93.
145. Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989; 25(3): 252-9.
146. Symington GR, Leonard DP, Shannon PJ, Vajda FJ. Sodium valproate in Huntington's disease. Am J Psychiatry 1978; 135(3): 352-4.
147. Tan BK, Leijnse-Ybema HJ, Zee MF. Sodium valproate in Huntington's chorea. Clin Neurol Neurosurg 1976; 79(1): 62-5.
148. Barr AN, Heinze W, Mendoza JE, Perlik S. Long term treatment of Huntington disease with L-glutamate and pyridoxine. Neurology 1978; 28(12): 1280-2.
149. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clin Neuropharmacol 2005; 28(4): 188-90.
150. Stewart JT. Treatment of Huntington's disease with clonazepam. South Med J 1988; 81(1): 102.
151. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976; 1(8): 225-7.
152. Farrell DF, Hofmann WW. A quantitative evaluation of the effect of diazepam in Huntington's chorea. Arch Phys Med Rehabil 1968; 49(10): 586-91.
153. Nilsen JA. Valium Therapy of Huntington's Chorea. Am J Psychiatry 1964; 120: 1197-8.
154. Warick LH, Barrows HS. Treatment of Huntington's Chorea with Chlordiazepoxide (Librium). Bull Los Angel Neuro Soc 1964; 29: 17-21.
155. Haynes E, Blanchette J, Gericke OL. Experience with chlordiazepoxide in Huntington's chorea. Dis Nerv Syst 1962; 23: 326-8.
156. Albanese A, Cassetta E, Carretta D, Bentivoglio AR, Tonali P. Acute challenge with apomorphine in Huntingtons disease: a double-blind study, Clin Neuropharmacol 1995; 18(5): 427-34.
157. Corsini GU, Onali P, Masala C, Cianchetti C, Mangoni A, Gessa G. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch Neurol 1978; 35(1): 27-30.
158. Tolosa ES, Sparber SB. Apomorphine in Huntington's chorea: clinical observations and theoretical considerations. Life Sci 1974; 15(7): 1371-80.
159. Caraceni TA, Girotti F, Giovannini P, Pederzoli M, Parati EA. Effects of DA agonist in Huntington disease hyperkinesia. Ital J Neurol Sci 1980; 1(3): 155-61.
160. Frattola L, Albiazzati MG, Spano PF, Trabucchi M. Treatment of Huntington's chored with bromocriptine. Acta Neurol Scand 1977; 56(1): 37-45.
161. Kartzinel R, Hunt RD, Calne DB. Bromocriptine in Huntington chorea. Arch Neurol 1976; 33(7): 517-8.
162. Albano C, Cocito L. Huntington's chorea and bromocriptine. Arch Neurol 1979; 36(5): 322.
163. Loeb C, Roccatagliata G, Albano C, Besio G. Bromocriptine and dopaminergic function in Huntington disease. Neurology 1979; 29(5): 730-4.
164. Tsuneizumi T, Anai K, Aoba A, Yamaguchi N, Takagi H, Chishima T, et al. Effects of bromocriptine in Huntington chorea. Case report. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4): 823-9.
165. Bassi S, Albizzati MG, Corsini GU, Frattola L, Piolti R, Suchy I, et al. Therapeutic experience with transdihydrolisuride in Huntington's disease. Neurology 1986; 36(7): 984-6.
166. Stocchi F, Carta A, Berardelli A, Antonini A, Argenta M, Formica A, et al. Effects of terguride in patients with Huntington's disease. Clin Neuropharmacol 1989; 12(5): 435-9.
167. Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M. Acute treatment of Huntington's chorea with lisuride. J Neurol Sci 1983; 59(2): 247-53.
168. Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J Neurol Neurosurg Psychiatry 1989; 52(5): 631-5.
169. Como PG, Rubin AJ, O'Brien CF, Lawler K, Hickey C, Rubin AE, et al. A controlled trial of fluoxetine in nondepressed patients with Hungtington's disease. Mov Disord 1997; 12(3): 397-401.
170. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40(3): 701-8.
171. Shults C, Steardo L, Barone P, Mohr E, Juncos J, Serrati C, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986; 36(8): 1099-102.
172. Agid Y, Destee A, Lallemand A. Effect of a methionine-enkephalin analog in Huntington's disease. Adv Neurol 1983; 37: 299-304.
173. Vestergaard P, Baastrup PC, Petersson H. Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 1977; 56(3): 183-8.
174. Aminoff MJ, Marshall J. Treatment of Huntington's chorea with lithium carbonate. A double-blind trial. Lancet 1974; 1(7848): 107-9.
175. Aminoff MJ, Marshall J, Smith E, Wyke M. Cognitive function in patients on lithium therapy. Br J Psychiatry 1974; 125(0): 109-10.
176. Carman JS, Shoulson I, Chase TN. Huntington's chorea treated with lithium carbonate. Lancet 1974; 1(7861): 811.
177. Mattsson B. Huntington's chorea and lithium therapy. Lancet 1973; 1(7805): 718-9.
178. Dalen P. Lithium therapy in Huntington's chorea and tardive dyskinesia. Lancet 1973; 1(7794): 107-8.
179. Mattsson B, Persson SA. Huntington's chorea, lithium, and G.A.B.A. Lancet 1973; 2(7830): 684.
180. Mateo D, Gimenez-Roldan S. The effect of piracetana on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study. Neurologia. 1996; 11(1): 16-9.
181. Destee A, Petit H, Warot P. Effect of piracetain in Huntington's chorea. Eur Neurol 1984; 23(2): 89-91.
182. Aquilonius SM, Eckernas SA. Choline therapy in Huntington chorea. Neurology 1977: 27(9): 887-9.
183. Davis KL, Hollister LE, Barchas JD, Berger PA. Choline in tardive dyskinesia and Huntington's disease. Life Sci 1976; 19(10): 1507-15.
184. Davis KL, Berger PA, Hollister LE, Simonton SC. Choline chloride in the treatment of Huntington's disease and tardive dyskinesia: a preliminary report. Psychopharmacol Bull 1977; 13(3): 37-8.
185. Davis KL, Hollister LE, Berger PA, Vento AL. Studies on choline chloride in neuropsychiatric disease: human and animal data. Psychopharmacol Bull 1978; 14(4): 56-8.
186. Brown WT, Sanberg PR, McGeer PL. Corticosteroids and chorea. Arch Neurol 1979; 36(7): 452-3.
187. Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol 1977, 34(12): 756-8.
188. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986, 47(8): 423-6.
189. Caro AJ, Caro S. Vitamin E in treatment of Huntington's chorea. Br Med J 1978; 1(6106): 153.
190. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978; 13(1): 23-49.
191. Walker FO, Hunt VP. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989; 12(4): 322-30.
192. Dupont E, Hansen AP, Juul-Jensen P, Lundbaek K, Magnussen I, de Fine Olivarius B. Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities. Acta Neurol Scand 1978; 57(6): 488-93.
193. Nutt JG, Rosin A, Chase TN. Treatment of Huntington disease with a cholinergic agonist. Neurology 1978: 28(10): 1061-4.
194. Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN. Effect of an opiate antagonist on movement disorders. Arch Neurol 1978; 35(12): 810-1.
195. Nutt JG. Effect of cholinergic agents in Huntington's disease: a reappraisal. Neurology 1983; 33(7): 932-5.
196. Nutt JG, Morgan NT. Acute effects of scopolamine in Huntington's disease. Adv Neurol 1983; 37: 291-7.
197. Tan BK, Leijnse-Ybema HJ, Brand HJvd. Levodopa in Huntington's chores. Lancet 1972; 1(7756): 903.
198. Shoulson I, Chase TN, Roberts E, Van Balgooy JN. Huntington's disease: treatment with imidazole-4-acetic acid. N Engl J Med 1975; 293(10): 504-5.
199. Mattsson B, Bertilsson L. Treatment with disulfiram in huntington's chorea. Acta Psychiatr Scand Suppl 1974; 255: 261-8.
200. Schenk G, Leijnse-Ybema HJ. Huntington's chorea and levodopa. Lancet 1974; 1(7853): 364.
201. De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntingtons disease. Psychopharmacology (Berl) 2001; 153(2): 264-6.
202. Chari S, Quraishi SH, Jainer AK. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. Pharmacopsychiatry 2003; 36(1): 41-3.
203. Braham J. Isoniazid therapy for Huntington disease. Neurology 1981; 31(12): 1580-1.
204. Muller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999; 14(6): 1038-40.
205. Nuti A, Maremmani C, Ceravolo R, Pavese N, Bonuccelli U, Muratorio A. Dexamethasone therapy in Huntington chorea: preliminary results. Riv Neurol 1991; 61(6): 225-7.
206. Bonuccelli U, Nuti A, Maremmani C, Ceravolo R, Muratorio A. Steroid therapy in Huntington's disease. Adv Biochem Psychopharmacol 1992; 47: 149-54.
207. Amsterdam JD, Dubin W. Huntington's Chorea and dimethyl-aminoethanol (deanol). J Clin Psychiatry 1978; 39(7): 626-8.
208. Merskey H. A clinical and psychometric study of the effects of procaine amide in Huntington's chorea. J Ment Sci 1958; 104(435): 411-20.
209. Bruyn GW. Some considerations on Huntington's chorea, in connection with a case, treated with procaine-amide. Folia Psychiatr Neurol Neurochir Neerl 1958; 61(3): 375-8.
210. Ganguli LK. Procaineamide hydrochloride in Huntington's chorea. J Indiana State Med Assoc 1956; 26(7): 274-5.
211. Cohen C. Huntington's chorea, with a report on a case treated with procaine amide. East Afr Med J 1956; 33(3): 104-7.
212. Lazarte JA, Baars CW, Pearson JS. Results in the treatment of Huntington's chorea with procaine amide hydrochloride. Am J Med Sci 1955; 229(6): 676-7.
213. Demyer W, Dyken M. Oral procaine amide treatment of Huntington's chorea. Am J Med Sci 1954; 228(1): 70-2.
214. Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A. Longlasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 1999; 53(7): 1605-6.
215. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, et al. Functional decline in Huntington's disease. Mov Disord 1995; 10(2): 211-4.
216. Louis ED, Anderson KE, Moskowitz C, Thorne DZ, Marder K. Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. Arch Neurol 2000, 57(9): 1326-30,
217. Hausdorff JM, Cudkowicz; ME, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 1998; 13(3): 428-37.
218. Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V. Velocity modulation and rhythmic synchronization of gait in Huntington's disease. Mov Disord 1999; 14(5): 808-19.
219. Westphal C. Über eine dem Bilde der cerebrospinalen grauen Degeneration ähnlichen Erkrankung des centralen Nervensystems ohne anatomischen Befund, nebst einigen Bemerkungen über paradoxe Contraktionen. Arch Psychiatr Nervenkr 1883; 14: 187-234.
220. Bird MT, Paulson GW. The rigid form of Huntington's chorea. Neurology 1971: 21(3): 271-6.
221. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000; 68(2): 238-41.
222. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosturg Psychiatry 1998; 65(4): 577-9.
223. Bonelli RM, Niederwieser G, Diez J, Gruber A, Koltringer P. Pramipexole Ameliorates Neurologic and Psychiatric Symptoms in a Westphal Variant of Huntington's Disease. Clin Neuropharmacol 2002; 25(1): 58-60.
224. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. Ann Pharmacother 2004; 38(7-8): 1194-6.
225. Van Vugt JP, Stijl M, Roos RA, van Dijk JG. Impaired antagonist inhibition may contribute to akinesia and bradykinesia in Huntington's disease. Clin Neurophysiol 2003; 114(2): 295-305.
226. Quarrell O, Harper P. The clinical neurology of Huntington's disease. In: Harper PS, editor. Huntingtons disease. 2nd ed. London: Saunders 1996; p. 31-72.
227. Vogel CM, Drury I, Terry LC, Young AB. Myoclonus in adult Huntington's disease. Ann Neurol 1991; 29(2): 213-5.
228. Kereshi S, Schlagenhauff RE, Richardson KS. Myoclonic and major seizures in early adult Huntingtons chorea: case- report and electro-clinical findings. Clin Electroencephalogr 1980; 11(2): 44-7.
229. Previdi P, Borgonovi R. Myoclonus and Huntington's chorea: description of a case. Ital J Neurol Sci 1980; 1(3): 189-91.
230. Novom S, Danna S, Goldberg MA. Intention myoclonus in Huntington's disease. Bull Los Angeles Neurol Soc 1976; 41(2): 82-4.
231. Wheeler JS, Sax DS, Krane RJ, Siroky MB. Vesico-urethral function in Huntington's chorea. Br J Urol 1985; 57(1): 63-6.
232. Cochen, Degos JD, Bachoud-Levi AC. Efficiency of carbamazepine in the treatment of micturitional disturbances in huntington disease. Neurology 2000; 55(12): 1934.
233. Nash MC, Ferrell RB, Lombardo MA, Williams RB. Treatment of bruxism in Huntington's disease with botulinum toxin. J Neuropsychiatry Clin Neurosci 2004 Summer; 16(3): 381-2.
234. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996: 11(2): 136-42.
235. Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Onset symptoms in 510 patients with Huntington's disease. J Med Genet 1993; 30(4): 289-92.
236. Mayberg HS, Starkstein SE, Peyser CE, Brandt J, Dannals RF, Folstein SE. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology 1992; 42(9): 1791-7.
237. Folstein S, Abbott MH, Chase GA, Jensen BA, Folstein MF. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 1983; 13(3): 537-42.
238. Whittier JR, Haydn GO, Crawford MA. Effect of imipramine on depression and hyperkinesia in Huntington's disease. Am J Psychiatry 1962; 118: 79.
239. Whittier J, Haydu G, Crawford J. Effect of imipramine (Tofranil) on depression and hyperkinesia in Huntington's disease. Am J Psychiatry 1961; 118: 79.
240. Patel SV, Tariot PN, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry 1996; 8(1): 23-6.
241. Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatr 1986; 149: 654-6.
242. Moldawsky RJ. Effect of amoxapine on speech in a patient with Huntington's disease. Am J Psychiatry 1984; 141(1): 150.
243. Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother 2003; 37(3): 452.
244. Jensen P, Sorensen SA, Fenger K, Bolwig TG. A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls, Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br J Psychiatry 1993; 163: 790-7.
245. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54(2): 452-8.
246. Mendez MF. Huntington's disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 1994; 24(3): 189-208.
247. Jensen P, Fenger K, Bolwig TG, Sorensen SA. Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls. J Neurol Neurosurg Pyschiatry 1998; 65(4): 467-71.
248. Stewart JT, Mounts ML, Clark RL, Jr. Aggressive behavior in Huntington's disease: treatment with propranolol. J Clin Psychiatry 1987; 48(3): 106-8.
249. Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. J Clin Psychiatry 1987; 48(9): 385-6.
250. Von Hafften AH, Jensen CF. Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease. J Clin Psychiatry 1989; 50(6): 230-1.
251. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996; 8(3): 338-40.
252. Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics 1997; 38(4): 389-91.
253. Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry 1994; 151(7): 1097.
254. Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics 1993; 34(5): 460-1.
255. Blass DM, Steinberg M, Leroi I, Lyketsos CG. Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. Am J Psychiatry 2001; 158(12): 1966-72
256. Fedoroff JP, Peyser C, Franz ML, Folstein SE. Sexual disorders in Huntington's disease. J Neuropsychiatry Clin Neurosci 1994; 6(2): 147-53.
257. Rich SS, Ovsiew F. Leuprolide acetate for exhibitionism in Huntington's disease. Mov Disord 1994; 9(3): 353-7.
258. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord 2000; 15(1): 173-6.
259. de Tommaso M, Specchio N, Sciruicchic, V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004; 19(12): 1516-8.
260. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol 2002; 9(6): 689-90.
261. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002; 13(1): 29-33.
262. Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13(1): 123-6.
263. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: An open label study. Neurology 2003; 60(5): 883-4.
264. Anderson KE, Louis ED, Stern Y, Marder KS. Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am J Psychiatry 2001; 158(5): 799-801.
265. Patzold T, Brune M. Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(3): 216-9.
266. Royuela Rico A, Gil-Verona JA, Macias Fernandez JA. A case of obsessive symptoms in Huntington's disease. Actas Esp Psiquiatr 2003; 31(6): 367-70.
267. Caine ED, Shoulson I. Psychiatric syndromes in Huntington's disease. Am J Pyschiatry 1983; 140(6): 728-33:
268. Stewart JT. Huntington's disease and propranolol. Am J Psychiatry 1993; 150(1): 166-7.
269. Bates GP, Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Curr Opin Neurol 2003; 16(4): 465-70.
270. Hersch SM. Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Curr Opin Neurol 2003; 16(4): 501-6.
271. Rosser A, Dunnett S. New drugs for Huntington's disease. Neuroreport 2002; 13(2): A21-2.
272. McMurray SE, McMurray CT. Huntington's disease. A sports star and a cook. Lancet 2001; 358 Suppl: S38.
273. Orr HT, Zoghbi HY. Reversing neurodegeneration: a promise unfolds. Cell 2000; 101(1): 1-4.
274. Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc Natl Acad Sci USA 2001; 98(1): 3-4.
275. Hughes RE, Olson JM. Therapeutic opportunities in polyglutamine disease. Nat Med 2001; 7(4): 419-23.
276. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61(1): 141-2.
277. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64(9): 1655-6.
278. Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassourridis A, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005; 252(1): 36-41.
279. Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61(7): 925-30.
280. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65(2): 286-92.
281. Berger A. Minocycline slows progress of Huntington's disease in mice. BMJ 2000; 321(7253): 70.
282. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6(7): 797-801.
283. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19(6): 337-42.
284. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004; 19(6): 692-5.
285. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology, 2004; 63(3): 547-9.
286. Denovan-Wright EM, Devarajan S, Dursun SM, Robertson HA. Maintained improvement with minocycline of a patient with advanced Huntington's disease. J Psychopharmacol 2002; 16(4): 393-4.
287. Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998; 50(5): 1366-73
288. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry 1995; 152(12): 1771-5.
289. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al. A controlled trial of idebenone in Huntington's disease. Mov Disord 1996; 11(5): 549-54.
290. Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999; 53(5): 1000-11.
291. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996; 11(3): 321-3.
292. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of eoenzyme Q10. Ann Neurol 1997; 41(2): 160-5.